Association between non-adherence to statins and hospitalization for cardiovascular disease and all-cause mortality in a national cohort

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 11, 2014, Pages 948-956

  Shin, Sukyoun ^a   Jang, Sunmee ^b   Lee, Tae Jin ^c   Kim, Ho ^c  

^a Health Insurance Review and Assessment Services   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

All cause mortality; Cardiovascular disease; Medication adherence; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEALTH INSURANCE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; PATIENT COMPLIANCE; RISK FACTOR; SOUTH KOREA; AGE; CARDIOVASCULAR DISEASES; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84920108902     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202132     Document Type: Article

References (31)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104: 2746-2753. CrossRef PubMed
2. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL; American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006; 113: e873-e923. PubMed
3. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011; 107: 1662-1666. CrossRef PubMed
4. Latry P, Molimard M, Dedieu B, Couffinhal T, Bégaud B, Martin-Latry K. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovasc Disord. 2011; 11: 46. CrossRef PubMed
5. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380: 581-590. CrossRef PubMed
6. Bouchard MH, Dragomir A, Blais L, Bérard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007; 63: 698-708. CrossRef PubMed
7. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Metaanalysis of randomized trials. Int J Clin Pharmacol Ther. 2003; 41: 567-577. CrossRef PubMed
8. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371: 117-125. CrossRef PubMed
9. Korean National Statistical Office. Available from http://kostat.go.kr/portal/korea/index.action [accessed 1 December 2013].
10. Korea Centers for Disease Control and Prevention. Korea National Health and Nutrition Examination Survey (KNHANES V-1). Available from https://knhanes.cdc.go.kr/knhanes/index.do [accessed 1 December 2013].
11. Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol. 2008; 66: 706-716. PubMed
12. Perreault S, Ellia L, Dragomir A, Côté R, Blais L, Bérard A, Lalonde L. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009; 122: 647-655. CrossRef PubMed
13. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008; 121: 24-33. CrossRef PubMed
14. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278. CrossRef PubMed
15. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008; 62: 76-87. CrossRef PubMed
16. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006; 15: 565-574; discussion 575-567.
17. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009; 25: 2303-2310. CrossRef PubMed
18. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 2000; 29: 891-898. CrossRef PubMed
19. Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012; 34: 190-199. CrossRef PubMed
20. Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, Lavikainen P, Jula A, Junnila SY, Kettunen R, Huupponen R. Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol. 2011; 71: 766-776. CrossRef PubMed
21. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009; 169: 260-268. CrossRef PubMed
22. Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA, Masoudi FA, Magid DJ, Havranek EP. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail. 2011; 17: 664-669. CrossRef PubMed
23. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 1: CD004816. PubMed
24. Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care. 2007; 45 (Suppl 2): S58-S65. CrossRef PubMed
25. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119: 3028-3035. Cross-Ref PubMed
26. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008; 46: 1125-1133. CrossRef PubMed
27. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009; 12: 989-995. Cross-Ref PubMed
28. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999; 37: 846-857. CrossRef PubMed
29. Kettani FZ, Dragomir A, Côté R, Roy L, Bérard A, Blais L, Lalonde L, Moreau P, Perreault S. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009; 40: 213-220. CrossRef PubMed
30. Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F. Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. BMC Neurol. 2012; 12: 117. CrossRef PubMed
31. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166: 1842-1847. CrossRef PubMed